Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Ketogenic Dietary Intervention in Men With Mild-to-Moderate COPD (COPDKETO)

5. august 2026 oppdatert av: Dursun Alper YILMAZ, Agri Ibrahim Cecen University

Effects of an 8-Week Ketogenic Dietary Intervention on Pulmonary Function, Systemic Inflammation, Body Composition, and Functional Exercise Capacity in Men With Mild-to-Moderate Chronic Obstructive Pulmonary Disease: A Pilot Randomized Controlled Trial

Chronic obstructive pulmonary disease (COPD) is associated with persistent airflow limitation, systemic inflammation, reduced exercise capacity, and unfavorable changes in body composition. Nutritional interventions may represent a complementary strategy to improve clinical outcomes in individuals with COPD.

This pilot randomized controlled trial evaluates the feasibility, safety, and preliminary effectiveness of an 8-week ketogenic dietary intervention in men with mild-to-moderate COPD. Participants are randomly assigned to either a supervised ketogenic diet or a control group receiving standard dietary advice. The ketogenic diet restricts carbohydrate intake and promotes nutritional ketosis, which is monitored using blood beta-hydroxybutyrate measurements.

The primary outcome is change in the FEV1/FVC ratio. Secondary outcomes include systemic inflammation assessed by C-reactive protein (CRP), phase angle measured by bioelectrical impedance analysis, functional exercise capacity assessed by the 6-minute walk test, estimated aerobic capacity, body composition, and selected biochemical safety markers. The study aims to provide preliminary evidence regarding whether a ketogenic dietary approach may improve inflammatory status, functional capacity, and physiological outcomes in individuals with COPD.

Studieoversikt

Detaljert beskrivelse

Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disorder characterized by persistent airflow limitation, chronic inflammation, exercise intolerance, and alterations in body composition. In addition to pulmonary impairment, systemic manifestations such as increased inflammatory burden, skeletal muscle dysfunction, and adverse metabolic changes contribute substantially to morbidity and reduced quality of life. Nutritional interventions have therefore emerged as potential adjunctive strategies in COPD management.

Ketogenic diets are characterized by marked carbohydrate restriction, moderate protein intake, and increased dietary fat consumption, resulting in nutritional ketosis. Potential mechanisms relevant to COPD include reductions in systemic inflammation, changes in substrate utilization, reductions in adiposity, and alterations in respiratory gas exchange. However, randomized controlled studies investigating ketogenic dietary interventions in COPD remain limited.

This study is an 8-week, single-center, parallel-group pilot randomized controlled trial conducted in clinically stable men with GOLD stage I-II COPD. Participants are randomly allocated in a 1:1 ratio to either a ketogenic dietary intervention or a control group receiving standard dietary advice. The ketogenic diet is individually prescribed by a dietitian and aims to provide approximately 60-70% of total energy from fat, 15-20% from protein, and 5-10% from carbohydrates, with carbohydrate intake restricted to less than 50 g/day.

Nutritional ketosis is monitored using capillary beta-hydroxybutyrate measurements obtained throughout the intervention period. Pulmonary function is assessed using spirometry. Body composition and phase angle are measured using multifrequency bioelectrical impedance analysis. Functional exercise capacity is evaluated using the 6-minute walk test, and estimated aerobic capacity is derived from walking performance. Blood samples are collected to assess inflammatory and safety-related biomarkers, including C-reactive protein, lipid parameters, alanine aminotransferase, and creatinine.

The primary objective is to determine whether an 8-week ketogenic dietary intervention improves FEV1/FVC compared with standard dietary advice. Secondary objectives are to evaluate effects on systemic inflammation, phase angle, exercise capacity, body composition, and biochemical safety outcomes. As a pilot trial, the study is designed to generate effect-size estimates, assess feasibility and adherence, and inform the design of future larger multicenter randomized controlled trials.

Studietype

Intervensjonell

Registrering (Faktiske)

34

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Male sex
  • Age between 40 and 75 years
  • Clinically stable chronic obstructive pulmonary disease (COPD)
  • GOLD stage I or II COPD
  • No acute COPD exacerbation within the previous 3 months
  • Stable pharmacological treatment for at least 4 weeks before enrollment
  • Ability to complete study assessments and comply with dietary instructions
  • Provision of written informed consent

Exclusion Criteria:

  • GOLD stage III or IV COPD
  • Uncontrolled cardiovascular disease
  • Chronic kidney disease
  • Severe hepatic dysfunction
  • Active malignancy
  • Insulin-dependent diabetes mellitus
  • Participation in another dietary intervention program within the previous 3 months
  • Inability to complete study assessments
  • Contraindications to dietary carbohydrate restriction
  • Refusal or inability to provide informed consent

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Ketogenic Diet
Participants received an individualized ketogenic dietary intervention for 8 weeks. The dietary prescription provided approximately 60-70% of total energy from fat, 15-20% from protein, and 5-10% from carbohydrates, with carbohydrate intake restricted to less than 50 g/day. Nutritional ketosis was monitored using blood beta-hydroxybutyrate measurements.
Participants received an individualized ketogenic dietary intervention for 8 weeks. The dietary prescription provided approximately 60-70% of total energy from fat, 15-20% from protein, and 5-10% from carbohydrates, with carbohydrate intake restricted to less than 50 g/day. Nutritional ketosis was monitored using blood beta-hydroxybutyrate measurements throughout the intervention period.
Aktiv komparator: Standard Dietary Advice
Participants received standard dietary recommendations for chronic obstructive pulmonary disease and were instructed to maintain their habitual dietary patterns throughout the 8-week study period.
Participants received standard dietary recommendations for chronic obstructive pulmonary disease and were instructed to maintain their habitual dietary patterns during the 8-week study period.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
FEV1/FVC Ratio
Tidsramme: Change in the ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC), assessed by spirometry after 8 weeks of intervention.
Baseline and Week 8
Change in the ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC), assessed by spirometry after 8 weeks of intervention.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
C-Reactive Protein (CRP)
Tidsramme: Baseline and Week 8
Serum C-reactive protein concentration (mg/L) measured as a marker of systemic inflammation.
Baseline and Week 8
Phase Angle
Tidsramme: Baseline and Week 8
Change in phase angle measured by multifrequency bioelectrical impedance analysis.
Baseline and Week 8
6-Minute Walk Distance
Tidsramme: Baseline and Week 8
Change in functional exercise capacity assessed by the 6-minute walk test.
Baseline and Week 8
Body Mass Index
Tidsramme: Baseline and Week 8
Baseline and Week 8Change in body mass index calculated as weight divided by height squared.
Baseline and Week 8
Fat Mass
Tidsramme: Baseline and Week 8
Baseline and Week 8Change in body fat mass measured by bioelectrical impedance analysis.
Baseline and Week 8
Estimated VO2max
Tidsramme: Baseline and Week 8
Baseline and Week 8Change in estimated maximal oxygen uptake derived from 6-minute walk performance.
Baseline and Week 8

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studiestol: Dursun Alper YILMAZ, Ağrı İbrahim Çeçen Üniversitesi

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. januar 2026

Primær fullføring (Faktiske)

15. mai 2026

Studiet fullført (Faktiske)

15. juni 2026

Datoer for studieregistrering

Først innsendt

15. juni 2026

Først innsendt som oppfylte QC-kriteriene

18. juni 2026

Først lagt ut (Faktiske)

23. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

7. august 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. august 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

IPD-planbeskrivelse

Individual participant data sharing has not yet been determined. Data sharing decisions will be made after publication of the primary study results and will be subject to institutional policies, ethical considerations, participant confidentiality requirements, and applicable data protection regulations.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere